In addition, we observe enrichment of ALDH1-stained cells in matched tumor-specimens obtained before and after neoadjuvant therapy with sorafenib and RT, whereas there was no evidence of CSC enrichment following clinical treatment with pazopanib. The gene discussed is ALDH1A1; the disease is neoplasm.